Insight

Alberto Giovanni Leone: Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma

Alberto Giovanni Leone/Linkedin

Oct 20, 2024, 13:01

Alberto Giovanni Leone: Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma

Alberto Giovanni LeoneChelsea and Westminster Hospital NHS Foundation Trust, shared a post on LinkedIn about his recent paper published in ESMO Open:

“In PD-L1 ‘low’ HER-2 negative gastroesophageal adenocarcinoma, the benefit of first-line ICI is modest.

Alternative therapeutic options such as zolbetuximab in Claudin18.2-positive disease must be taken into account.”

“Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups”

Authors: Alberto Giovanni Leone, Khi Yung Fong, Elizabeth Smyth, Joseph Zhao, Filippo Pietrantonio et al.

Alberto Giovanni Leone: Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma

Alberto Giovanni Leone is an HIV/Oncology Fellow at Chelsea and Westminster Hospital NHS Foundation Trust. He also serves as a Medical Oncology Resident at the IRCCS Foundation National Cancer Institute of Milan.

Alberto Giovanni Leone cancer Elizabeth Smyth ESMO Open Filippo Pietrantonio gastroesophageal adenocarcinoma Joseph Zhao Khi Yung Fong OncoDaily Oncology

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success